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Background: Photodynamic therapy (PDT) involves the activation of a 
photosensitiser by visible light to produce activated oxygen species within target cells, 
resulting in their destruction. Evidence-based guidelines support the efficacy of PDT 
using topical 5-aminolaevulinic acid (ALA-PDT) in actinic keratoses, Bowen’s 
disease and basal cell carcinoma (BCC). Efficacy for nodular BCC appears inferior to 
that for superficial BCC unless prior debulking or repeat treatments are performed. 
The aim of this study was to assess the safety and efficacy of adding a novel iron 
chelating agent, CP94 to topical ALA, to increase the accumulation of the 
photosensitiser in the tumour.  
 
Observations: Enhanced PDT using 40% CP94 resulted in significantly greater 
clearance rates in nodular BCC than with ALA-PDT alone, in our protocol of single 
treatment PDT with no lesion preparation. 
 
Conclusion: The results of this study demonstrate the safe and effective use of an 
enhanced ALA-PDT protocol for nodular BCC using CP94, with no adverse reactions 
to this modification. This is the first time this formulation has been used in patients.  
This formulation is now the focus of further study. 
 
Key Words: Photodynamic therapy; basal cell carcinoma; iron chelator; CP94; 
hydroxypyridinone.
 3 
INTRODUCTION 
 
Photodynamic therapy (PDT) is a sophisticated, selective method of ablating tissue. It 
involves the activation of a photosensitising drug by visible light to produce activated 
oxygen species within target cells, resulting in their destruction.1  
  
Topically active agents are preferable for PDT in dermatology and the most 
experience to date has been with the photosensitising agent ALA (5-aminolaevulinic 
acid, ALA) prepared as a cream2. This is a precursor in the haem biosynthesis 
pathway, which occurs in all nucleated cells. Administration of ALA results in the 
formation of the endogenous photosensitiser, protoporphyrin IX (PpIX). This 
molecule normally binds with iron to form haem1. PDT then involves the in situ 
activation of the pre-administered photosensitiser (in this case ALA-derived PpIX) by 
a specific wavelength of light (635 nm) in the presence of molecular oxygen resulting 
in necrosis/apoptosis of the tumour cells1. 
 
ALA-PDT for the treatment of the most common form of skin cancer, basal cell 
carcinoma (BCC) has received considerable attention in recent years. There is a 
substantial subset of BCC which are currently difficult to treat by conventional 
therapies because of size, site or multiple lesion presentation. Topical PDT may be 
advantageous in these situations and is associated with excellent cosmesis also 
making it an attractive option for cosmetically sensitive sites3. Results show that PDT 
produces good results as long as the disease remains superficial4. Efficacy for nodular 
BCC however appears inferior to standard treatment unless prior debulking or repeat 
treatments are performed5,6 Clearance rates for ALA-PDT in superficial and nodular 
BCC are highly variable, with average rates of 87% and 53% respectively for 12 
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studies treating 826 superficial and 208 nodular BCC7. It is important therefore to try 
and improve treatment in these thicker lesions, and various adaptations to the standard 
treatment have been considered. 
 
One proposed method for increasing efficacy is to increase the levels of the 
photosensitiser, PpIX within cells (which are already being treated with maximal 
ALA doses), through the addition of an iron chelating agent. In vitro studies have 
shown that by using an iron chelator, the conversion of PpIX to haem is inhibited by 
removing Fe2+ from the cellular system, resulting in an increased temporary 
accumulation of PpIX, which can then be utilised for PDT (Figure1). In addition to 
this, the resultant low intracellular iron concentration also inhibits translation of ALA 
synthase mRNA, which would normally be a major point of regulation for this 
pathway8.  
Iron chelators such as desferrioxamine (DFO) and ethylenediamine tetraacetic acid 
(EDTA) have been investigated as potential enhancers of ALA-PDT. Combinations of 
EDTA (a nonspecific chelator and antioxidant) and dimethylsulphoxide (DMSO, 
principally a penetration enhancer) have been used during ALA-PDT to try and 
increase treatment effect9,10. The combination of EDTA and DMSO with ALA, in 
comparison with ALA alone, indicates improved penetration of ALA and PpIX 
accumulation in BCC10 but there was no measurable increase in PpIX levels when 
EDTA was the only additive employed10,11. DFO, on the other hand, is both specific 
for iron and can penetrate into the cellular cytosol12 resulting in an increased 
enhancement of ALA-PDT12 
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Relatively little research has been conducted previously on the effects of the novel 
iron chelator, 1,2-diethyl-3- hydroxypyridin-4-one hydrochloride (CP94) (Figure 2) 
on ALA induced PDT. The hydroxypyridinones are a relatively new series of iron-
chelating agents. They are of lower molecular weight and greater lipophilicity than 
previously studied iron chelators, eg. DFO, facilitating absorption directly into the 
skin and they enter the intracellular iron pools rapidly, being neutrally charged13. 
They were originally developed to supersede DFO for the treatment of thalassaemia 
and other disorders of iron overload. They have greater affinity for iron than DFO 
being bidentate (rather than hexadentate), binding to iron in the ratio of 3:1, compared 
to 1:1 with DFO14. 
 
In vivo studies have shown that CP94 enhances porphyrin fluorescence and 
photosensitivity in all cell lines studied15. Recent studies by Pye and Curnow have 
shown that CP94 is superior to DFO at increasing PpIX fluorescence in cultured 
human cells16.  
 
Animal studies have shown that the outcome of ALA-PDT can be significantly 
enhanced by the addition of CP94.  Preliminary studies in a rat colonic tumour model 
have shown that CP94 can double the depth of effect produced by ALA alone and 
increase the volume of necrosis 7-fold17. A topical pilot study in normal rat skin 
showed that ALA-PDT + CP94 tripled the effect of ALA alone18. These findings 
however have not been applied clinically previously and the investigation reported 
here is the first to do so. Previous research has shown that CP94 can be administered 
orally to patients with iron-overload without significant toxicity to produce rapid and 
effective iron mobilization suggesting its safety in topical use as employed here19. It is 
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unlikely that CP94 will be absorbed to any extent into the plasma when applied 
topically to the skin and any systemic circulation will be rapidly cleared by first pass 
metabolism (glucoronidation) in the liver. 
 
The aim of this study, therefore, was to assess the safety and determine an indication 
of efficacy, of a simple pharmacological modification to single visit ALA-PDT for the 
treatment of nodular BCC (without prior debulking), by incorporating the novel iron 
chelating agent, CP94, into the ALA cream, to temporarily further enhance the 
accumulation of the active photosensitiser. By slowly increasing the concentration of 
CP94 the safety profile could be monitored in a controlled manner.  
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MATERIALS and METHODS 
A parallel, open, dose-escalating, pilot study was conducted by two centres: Royal 
Cornwall Hospital, Truro and Forth Valley Dermatology Centre (Stirling and Falkirk 
Royal Infirmary). 
 
Full ethical approval was obtained for the study and the Declaration of Helsinki 
protocols were followed. The patients were recruited from the standard outpatient 
clinic. Thirty six patients (23 males and 13 females) participated in the study, with a 
mean age of 72 years (range: 32-88 years). This number was chosen to establish the 
safety of this modified formulation. 
 
Each patient had a solitary, previously untreated, nodular BCC. Twenty lesions were 
located on the face or neck, seven on the limbs and nine on the trunk and back. 
Each lesion had a minimum diameter of 5 mm and a maximum diameter of 20 mm. 
Patients under the age of 18 and pregnant women were excluded from the study. 
Patients within the child-bearing years were only included if they were able to use 
adequate contraceptive measures. Patients taking photoactive drugs were excluded. 
After written informed consent was obtained, a 3 mm punch biopsy was taken from 
the area within the lesion which appeared clinically to be the thickest. A 5.0 Vicryl 
rapide suture was used to close the biopsy site. Histology was performed on each 
specimen including Breslow thickness. 
 
Six patients were treated in each of the control groups (ALA alone and CP94 alone) 
(control groups) and 6 patients were treated with each escalating dose of CP94, 3 per 
centre in parallel.  
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Two weeks following the biopsy, the patients were allocated into one of the following 
groups in strict order of recruitment at each centre:  
            1)   20% ALA alone (0% CP94) 
2) 20% ALA + 5% CP94 
3) 20% ALA + 10% CP94 
4) 20% ALA + 20% CP94 
5) 20% ALA + 40% CP94 
6) 40% CP94 alone (0% ALA) 
 
The lesions were digitally photographed and measured using skin landmarks to help 
isolate the exact area for future excision. Each lesion received one application of 
topical ALA (20% ALA w/w in Unguentum Merck cream base, Crawfords 
Pharmaceuticals, UK) +/- the various doses of the iron chelator CP94 w/w depending 
on the treatment group. The various concentrations of ALA with CP94 were made up 
in the pharmacy of each hospital under strict protocol, no more than 1 hour prior to 
application to the lesion. No prior lesion preparation was performed and 
approximately 2 mm thickness of the cream was applied to the whole lesion and a 5 
mm rim of surrounding normal skin, using a wooden spatula. The lesion was then 
covered with an occlusive dressing (Tegaderm® , 3M, Loughborough, UK) followed 
by a light occlusive Mepore® dressing as per the standard protocol for ALA-PDT. 
Patients were asked to comment on any adverse reactions such as irritation during the 
time of cream application and an observation of the treated area was made to assess 
any contact skin reaction such as erythema prior to irradiation.  
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Six hours following application of the cream, the lesion was illuminated by a filtered 
narrow-band (630 nm +/-15 nm) red xenon light source (Photo Therapeutics Limited, 
UK, 100 J/cm2, <130 mW/cm2). Six hours is the standard preillumination interval for 
ALA-PDT for BCC up to 2 mm thick 20 .This activating red light was delivered, in a 
continuous manner to the entire lesion and to at least a 5 mm margin of adjacent skin. 
The treatment regime employed, apart from the incorporation of the CP94, was 
therefore the same as our standard dermatological ALA-PDT protocol.  Pain levels 
during treatment were assessed by the patient on a 0-10 visual analogue scale. The 
patients were asked to grade their pain during illumination by drawing a line through 
a scale where 0 represented no pain and 10 represented intolerable pain. The treatment 
area was also assessed clinically, post irradiation to check for phototoxic reactions 
such as erythema. In all cases, at 6 weeks following the single PDT treatment, clinical 
response rate was assessed and surgical excision of the whole treatment site was 
undertaken for histology. Previous photographs, skin landmarks and precise 
measurements were used to ensure exact excision margins. Histolological 
examination was carried out on each specimen by the one dermatopathologist at each 
centre, using transverse bread slice histological examination and maximum Breslow 
thickness of the tumour was measured. The dermatopathologists were blinded in that 
they received the specimens without knowledge of the treatments received. Blood 
samples were taken for liver function tests prior to and 1 week following application 
of the iron chelator, to assess any adverse effect on liver function. 
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RESULTS 
Immediate clinical observations Whilst the cream was in contact with the skin, there 
was no report of any irritation or discomfort, in any of the patients. After removal of 
the cream at 6 hours there was no clinical evidence of increased erythema at the 
treatment site or surrounding area in those patients treated with ALA+CP94 over 
ALA alone and no other adverse reactions. Following illumination there were no 
adverse events, beyond the expected post therapy inflammatory response (erythema 
and oedema) normally observed with ALA-PDT. There was no increased erythemal 
response either lesional or paralesional in those patients receiving CP94-enhanced 
therapy.  
 
Pain response During light treatment, all patients tolerated therapy well without the 
need for local anaesthesia. There was no need for interruption to treatment in any of 
the cases. There was no correlation between pain and increasing concentrations of 
CP94 and this was confirmed by the patient’s pain perception scores from the visual 
analogue scale. The score on the visual analogue scale ranged from 2-5 in both ALA 
only and ALA+CP94 groups and with no increasing trend with addition of the iron 
chelator. Little or no pain was experienced by the patients receiving 40% CP94 alone 
(data not shown). 
 
Blood results Liver function tests were not altered in any of the patients following 
treatment.  
 
Histological results The clinical and histological response to all 36 treatment sites, 6 
weeks following the ALA-PDT treatment is shown in Table 1. In the CP94 control 
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group there was no clinical response to the PDT treatment at 6 weeks. This was 
confirmed using digital photography. All other lesions showed some clinical response, 
with the clinical impression matching the histological response in all cases. With 
ALA-PDT alone, 2 out of 6 histological specimens showed an actual increase in 
depth, or thickness, from the pre-treatment biopsy.  Similarly four out of the six ALA 
+ 5% CP94 treated nodular BCC group showed an increased thickness in the post 
treatment excision specimens. The reason for this could be twofold. Firstly any 
remaining BCC could have continued to grow in the 8-week period between biopsy 
and excision and secondly, the biopsy may not have been taken from the thickest part 
of the tumour even though it appeared to be so clinically. There was no significant 
improvement in response (i.e. reduction in tumour thickness) with the addition of 5% 
CP94 compared with the control groups (ALA alone or CP94 alone) (p < 0.172 and p 
< 0.79 respectively, unpaired student’s t-test). With increasing concentrations of CP94 
(10, 20 and 40%), the thickness of any tumour remaining in the excised specimens 
decreased in all cases (Figure 3). The addition of 40% CP94 showed a significant 
improvement in tumour response (i.e. reduction in tumour thickness after treatment) 
compared with both ALA and CP94 alone controls (p < 0.001 and p < 0.001 
respectively, unpaired student’s t-test). Some complete tumour responses were 
observed following PDT treatment (Figure 4), with 5 out of 6 showing complete or 
partial (greater than 50%)  histological response in the ALA + 40% CP94 group. The 
BCC lesion in this group which showed no response was a thicker tumour with a 
thickness of 3 mm prior to treatment and it was noted that in general, in all groups, the 
tumours greater than 3 mm prior to treatment seemed to respond less well than 
tumours less than 3 mm thick pre-treatment. Figures 3 and 4 demonstrate this 
increased trend towards complete clearance with increased concentrations of CP94, 
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both clinically and histologically. Overall there was a significant improvement in 
(histological) tumour response with the addition of the CP94 iron chelator (p < 0.001 
ANOVA).  
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DISCUSSION 
 
This safety study was designed to assess the clinical feasibility and potential 
advantage of the addition of CP94 to routine dermatological ALA-PDT in this first 
clinical investigation of this novel pharmacological modification.  
 
The results have shown that the addition of CP94 to ALA-PDT would appear to be 
safe, with no dose-limiting adverse events noted in any of the 30 patients treated with 
CP94 during this investigation. The CP94 mixed well with the 20% ALA with no 
apparent separation and was used immediately following preparation. Further studies 
to assess stability will be required in the future to increase convenience. There were 
no increased side effects such as erythema noted before or after illumination with 
increased concentrations of CP94, over that observed with the ALA only controls. 
This is in contrast to a study carried out applying different concentrations of ALA via 
iontophoresis, to normal skin previously treated with DFO, where there was a 
significant increase in erythema using ALA+ DFO compared with ALA alone21. 
 
 There was also no apparent increase in pain noted during illumination, when 
increasing concentrations of CP94 were employed. Pain during irradiation is one of 
the most frequent side effects that can be observed during dermatological PpIX-
induced PDT, so this finding was reassuring. Irradiation-induced pain is thought to be 
associated with an effective PDT treatment taking place. Previous studies however 
have shown that pain scores do not correlate with the intensity of PpIX fluorescence 
either during ALA-PDT of tape stripped normal skin20 or during ALA-PDT of skin 
cancer22. This suggests that pain associated with ALA-PDT is not simply due to the 
 14 
activation of PpIX alone. Additionally as ALA is transported into cells by gamma-
aminobutyric acid transporters which are prevalent in peripheral nerve endings, the 
cellular location of the PpIX on irradiation as well as the quantity is likely to be 
important. As only PpIX levels produced from endogenous ALA were present in the 
CP94 only control group, this may explain the lower pain scores obtained from these 
patients. 
 
This study has also shown encouraging results with regard to complete clearance of 
nodular BCC using this novel iron chelator, with no prior lesion preparation and only 
one cycle of enhanced PDT treatment (Figure 5). We would not normally expect a 
single standard ALA-PDT treatment to clear these lesions.  Standard routine therapy 
with methyl aminolaevulinic acid (MAL), involves two treatments, 7 days apart plus 
careful debulking of lesions before treatment, so the treatment modification presented 
here is of great interest. Lesions treated with ALA alone and with the lower 
concentrations of CP94 (<10%) showed no complete clearances but with increasing 
concentrations of CP94 we were beginning to see some increased response including 
some complete clearance of the tumours. Some of the thicker tumours were in the 
“ALA” alone group, which may have explained the much lower response rate in this 
group, but in general the average tumour thickness among the groups receiving the 
combined treatment was fairly similar, This problem is inherent in a study where 
patients are allocated to the various treatment groups in strict order rather than 
stratified by tumour thickness. The histological findings matched the clinical findings 
in all cases and clearly showed a higher PDT efficacy as shown by cytotoxicity, with 
increasing doses of CP94. 
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These findings are in contrast to studies using other iron chelating agents particularly 
DFO, where the addition of DFO to the higher ALA dose being employed in clinical 
treatment did not significantly enhance PpIX levels, when examined in matched 
lesions in the same patient21. CP94 however is of lower molecular weight and higher 
lipophilicity than DFO. It is also neutrally charged in both iron free and iron 
complexed forms enabling it to move freely in and out of cells by simple diffusion23. 
CP94 consequently enters the intracellular iron pools more readily and it is this factor 
which is most likely to account for the increased effect of CP94 over DFO. Studies 
support the efficacy of CP94 in the enhancement of ALA-PDT of normal colon and 
bladder tissue in animal models18, 24 and in normal and malignant cell lines15,16. 
Studies using digital imaging fluorescence microscopy have revealed inter- and 
intratumour fluorescence variability and heterogeneity in BCC treated with ALA for 
the standard 6 hours application time26 .A relatively stable level of fluorescence 
existed from the epidermis to some depth, after which a quantifiable gradient of 
decreasing PpIX fluorescence intensity versus depth was seen26.The ability of CP94 to 
increase PpIX fluorescence particularly in cells where the concentration of ALA is 
low  may explain the increased effect in deeper nodular tumours16. The addition of 
CP94 would enable the production of clinically useful amounts of PpIX deeper in the 
tumour cells, where otherwise PpIX production would be at sub-lethal levels. 
 
Further studies are now underway to explore and confirm these observations and to 
determine the optimal concentration of CP94 to achieve maximum effect. It may be 
expected that there will be a limit to the addition of the iron chelator to the mixture 
both physically and also beyond which there would be insufficient ALA present as a 
substrate, to further increase the levels of PpIX to produce greater enhancement of 
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treatment effect.  Studies are also underway to measure the time taken to achieve 
maximum PpIX concentration with increasing doses of CP94 as it may be possible to 
allow shorter drug-light intervals if PpIX formation is optimised sooner particularly 
when treating superficial disease. 
 
The combined use of ALA+CP94 in conjunction with penetration enhancers such as 
DMSO, tape stripping or iontophoresis, or the use of pressure techniques such as 
oxygen pressure injection (OPI)27 may further increase the proportion of nBCC 
completely responding to PDT treatment. 
 
This study therefore has indicated that this enhanced therapy with CP94 provides a 
simple and safe pharmacological modification to dermatological ALA-PDT which 
may increase the proportion of BCC that can be treated by this therapy. This may be a 
real advance in improving the response rate in these nodular tumours without the need 
for repeat treatment cycles, although this will require confirmation in a large 
randomised controlled trial. 
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Table 1.  
 
Clinical and histological response in each patient following PDT with 
20% ALA and increasing concentrations of CP94. 
 
NR: Nil Response: Less than 50% reduction in tumour depth compared  
       with pre-treatment biopsy. 
PR: Partial Response: Greater than 50% reduction in tumour depth 
       compared with pre-treatment biopsy. 
CR: Complete Response: No residual cells seen. 
 
 *      ulcerated 
 **    residual superficial BCC- central fibrosis  
 ***  small focus of BCC at 1.4mm  
 ****virtually clear-one focus of BCC on one section only 
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Figure Legends 
 
Figure 1. Schematic diagram of haem biosynthesis indicating the 
difference in PpIX and haem production with and without the iron 
chelating agent being present. 
 
Figure 2. Molecular structure of the iron chelator CP94 (1,2-diethyl-3-
hydroxypyridin-4-one hydrochloride). 
 
Figure 3. Tumour thickness before and after PDT treatment of each 
group of nBCC lesions (n=6) with increasing concentrations of CP94 
incorporated. 
 
  0% ALA + 40% CP94 
20% ALA +   0% CP94 
20% ALA +   5% CP94 
20% ALA + 10% CP94 
20% ALA + 20% CP94 
20% ALA + 40% CP94 
 
 
Figure 4. Scatter diagram indicating percentage reduction or increase in 
tumour thickness of individual nBCC lesions produced using ALA-PDT 
in combination with increasing concentrations of the iron chelator, CP94. 
 
   Nil Response 
 Partial Response 
 Complete Response 
 
  
 
Figure 5.  
a) Nodular BCC right side of nose before treatment with ALA-PDT. 
b) Nodular BCC 6 weeks after PDT treatment prior to excision 
using 20% ALA+ 40% CP94 showing almost complete clinical clearance 
and excellent cosmesis. 
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Formulation Size 
(mm) 
Site Initial 
tumour 
thickness 
(mm) 
Tumour 
thickness 
on 
excision 
(mm) 
Clinical 
Outcome 
Histological 
Outcome & 
% reduction/ 
increase from 
biopsy 
40% CP94 20x12 Limb 1.2 1.2 NR NR      0% 
40% CP94 18x9 Back 1.8 1.6 NR NR     -11% 
40% CP94 20x13 Limb 1.2 1.0 NR NR     -17% 
40% CP94 20x13 Trunk 1.3 3.3* NR NR  + >100% 
40% CP94 18x16 Back 0.7 0.9 NR NR      +29% 
40% CP94 19x12 Trunk 0.9 1.1 NR NR      +22% 
ALA alone 19x10 Trunk 3.2 2.6 PR NR       -18% 
ALA alone 15x12 Face 2.3 1.5 PR NR       -34% 
ALA alone 12x12 Face 2.3 1.5 PR NR       -34% 
ALA alone 10x15 Face 2.3 2.7 PR NR      +17% 
ALA alone 12x8 Limb 2.5 3.1 PR NR      +24%  
ALA alone 15x15 Limb 2.4 1.8 PR NR       -25% 
ALA+5%CP94 10x10 Face 1.0 1.7 PR NR      +70% 
ALA+5%CP94 12x10 Face 3.7 1.0 PR PR       -73% 
ALA+5%CP94 20x15 Back 0.1 2.5 PR NR  +>100%  
ALA+5%CP94   5x5 Neck 1.8 1.6 PR NR       -11% 
ALA+5%CP94 17x7 Face 2.0 3.0 PR NR       +50%         
ALA+5%CP94 10x10 Face 2.2 3.0 PR NR       +36%         
ALA+10%CP94 12x10 Face 1.2 0 CR CR        - 100% 
ALA+10%CP94 10x10 Limb 1.9 1.4 PR NR       - 26% 
ALA+10%CP94 17x11 Face 2.2 1.7 PR NR       - 23% 
ALA+10%CP94 15x15 Limb 0.3 0.1** PR PR        -67% 
ALA+10%CP94 10x10 Face 2.0 0.3 PR PR       - 85% 
ALA+10%CP94 12x10 Face 1.6 1.0 PR NR        -37% 
ALA+20%CP94 10x10 Face 0.7 0 CR CR         -100% 
ALA+20%CP94 10x11 Face 3.2 3.0 PR NR        - 6% 
ALA+20%CP94 20x18 Back 2.0 1.7 PR NR        - 5% 
ALA+20%CP94 12x9 Face 3.0 1.4*** PR PR        -53% 
ALA+20%CP94   9x7 Face 2.0 0.4**** PR PR        -80% 
ALA+20%CP94 10x7 Face 1.4 0 CR CR       -100% 
ALA+40%CP94 12x13 Face 2.0 0.4 PR PR        -80% 
ALA+40%CP94 15x16 Trunk 3.0 2.0 PR NR        -33% 
ALA+40%CP94   9x10 Neck 1.25 0 CR CR       -100% 
ALA+40%CP94   6x7 Limb 1.5 0.12 PR PR        - 92% 
ALA+40%CP94 10x12 Trunk 2.0 0 CR CR       -100% 
ALA+40%CP94   6x6 Face 2.0 0.8 PR PR        - 60% 
 
Table 1 
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Fig. 1 
 
 
 
 
 
5 Aminolaevulinic 
Acid 
5 Aminolaevulinic 
Acid 
Protoporphyrin IX Protoporphyrin IX 
Haem Haem 
Fe2+ Ferrochelatase Fe2+ Ferrochelatase 
Iron Chelator 
 24 
 
 
 
 
 
Fig. 2 
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Fig. 3 
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Fig. 5a 
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Fig.5b  
 
 
 
 
 
 
 
 
 
 
 
